Guggenheim upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks reports. Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. […]

American Bitcoin (NASDAQ:ABTC – Get Free Report) was upgraded by equities researchers at BTIG Research to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks reports. Several other analysts have also recently weighed in on the stock. Wall Street Zen cut shares of American Bitcoin from a “hold” rating […]

First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) was upgraded by equities research analysts at Guggenheim to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports. Other equities research analysts also recently issued reports about the stock. Wolfe Research assumed coverage on shares of First Tracks Biotherapeutics in a report on Tuesday, […]

UBS Group upgraded shares of Cyclerion Therapeutics (NASDAQ:KRSA – Free Report) to a strong-buy rating in a report published on Thursday morning,Zacks reports. Separately, Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating and one has given […]

Lifesci Capital upgraded shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports. Several other analysts also recently weighed in on VTVT. BTIG Research boosted their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in […]

Lucid Cap Mkts upgraded shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks reports. A number of other brokerages also recently weighed in on NVCT. Roth Capital boosted their target price on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the […]